Safety of biologic agents for psoriasis in patients with viral hepatitis

Journal of Dermatological Treatment

Volumn 29, Issue 6, 2018, Pages 553-556

  AlMutairi, Nawaf ^a   Abouzaid, Hesham Alaadin ^b  

^a KUWAIT UNIVERSITY   (Kuwait)

^b FARWANIYA HOSPITAL   (Kuwait)

Author keywords

biologics; Psoriasis; reactivation; viral hepatitis

Indexed keywords

BIOLOGICAL PRODUCT; LIVER ENZYME; VIRUS DNA; BIOLOGICAL FACTOR; USTEKINUMAB; VIRUS ANTIBODY; VIRUS RNA;

ADULT; ARTICLE; BIOLOGICAL THERAPY; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONCURRENT INFECTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LIVER FAILURE; MALE; MIDDLE AGED; PRIORITY JOURNAL; PSORIASIS; TREATMENT DURATION; VIRUS HEPATITIS; VIRUS REACTIVATION; AGED; BLOOD; CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; COMPLICATION; ENZYMOLOGY; GENETICS; HEPACIVIRUS; HEPATITIS B VIRUS; IMMUNOLOGY; LIVER; METABOLISM; VIROLOGY; VIRUS LOAD; YOUNG ADULT;

ADULT; AGED; ANTIBODIES, VIRAL; BIOLOGICAL FACTORS; DNA, VIRAL; FEMALE; HEPACIVIRUS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; LIVER; MALE; MIDDLE AGED; PSORIASIS; RNA, VIRAL; USTEKINUMAB; VIRAL LOAD; YOUNG ADULT;

EID: 85041590399     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.1080/09546634.2018.1430301     Document Type: Article

References (33)

1. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58:826–850.
2. Dong J, Goldenberg G., New biologics in psoriasis: an update on IL-23 and IL-17 inhibitors. Cutis. 2017;99:123–127.
3. Norris D, Photiou L, Tacey M, et al. Biologics and dermatology life quality index (DLQI) in the Australasian psoriasis population. J Dermatolog Treat. 2017;23:1–6.
4. Wu JJ, Poon KY, Channual JC, et al. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. Arch Dermatol. 2012;148:1244–1250.
5. Bonifati C, Lora V, Graceffa D, et al. Management of psoriasis patients with hepatitis B or hepatitis C virus infection. World J Gastroenterol. 2016;22:6444–6455.
6. Pathirana D, Ormerod AD, Said P, etet al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol. 2009;23(Suppl 2):S1–S70.
7. Calabrese LH, Zein N, Vassilopoulos D., Safety of anti-tumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infections. Ann Rheum Dis. 2004;63(Suppl II):18–24.
8. Kalb RE, Fiorentino DF, Lebwohl MG, et al. Risk of serious infection with biologic and systemic treatment of psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). JAMA Dermatol. 2015;151:961–969.
9. Domm S, Cinatl J, Mrowietz U., The impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections: a review of the literature. Br J Dermatol. 2008;159:1217–1228.
10. Salvi M, Macaluso L, Luci C, et al. Safety and efficacy of anti-tumor necrosis factors α in patients with psoriasis and chronic hepatitis C. WJCC. 2016;4:49–55.
11. Snast I, Atzmony L, Braun M, et al. Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: a retrospective cohort study and systematic review of the literature. J Am Acad Dermatol. 2017;77:88–97.e5.
12. Kwon H, Lok AS., Hepatitis B therapy. Nat Rev Gastroenterol Hepatol. 2011;8:275–284.
13. Lok AS, Lai CL, Wu PC, et al. Spontaneous hepatitis B e-antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. Gastroenterol. 1987;92:1839–1843.
14. Torres HA, Davila M., Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer. Nat Rev Clin Oncol. 2012;9:156–166.
15. Lan JL, Chen YM, Hsieh TY, et al. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy. Ann Rheum Dis. 2011;70:1719–1725.
16. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349:2014–2022.
17. Alter MJ., Epidemiology of hepatitis B in Europe and worldwide. J Hepatol. 2003;39(Suppl 1):S64–S69.
18. Lavanchy D., The global burden of hepatitis C. Liver Int. 2009;29:74–81.
19. Fotiadou C, Lazaridou E, Ioannides D., Safety of anti-tumor necrosis factor-a agents in psoriasis patients who were chronic hepatitis B carriers: a retrospective report of seven patients and brief review of the literature. J Eur Acad Dermatol Venereol. 2011;25:471–474.
20. Cho YT, Chen CH, Chiu HY, et al. Use of anti-tumor necrosis factor-α therapy in hepatitis B virus carriers with psoriasis or psoriatic arthritis: a case series in Taiwan. J Dermatol. 2011;39:269–273.
21. Nosotti L, Francesconi F, Izzi S, et al. Safety of anti-tumor necrosis factor-alpha therapy in psoriatic patients with hepatitis B virus infection. Br J Dermatol. 2010;162:1408–1410.
22. Navarro R, Vilarrasa E, Herranz P, et al. Safety and effectiveness of ustekinumab and anti-tumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting. Br J Dermatol. 2013;168:609–616.
23. Motaparthi K, Stanisic V, Van Voorhees AS, Medical Board of the National Psoriasis Foundation, et al. From the Medical Board of the National Psoriasis Foundation: recommendations for screening for hepatitis B infection prior to initiating anti-tumor necrosis factor-alfa inhibitors or other immunosuppressive agents in patients with psoriasis. J Am Acad Dermatol. 2014;70:178–186.
24. Lok AS, McMahon BJ., Chronic hepatitis B: update 2009. Hepatology. 2009;50:661–662.
25. European Association For The Study Of The Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167–185.
26. Sanz-Bueno J, Vanalclocha F, Garcia-Doval I, et al. Risk of reactivation of Hepatitis B virus infection in psoriasis patients treated with biologics: a retrospective analysis of 20 cases from the BIOBADADERM database. Actas Dermo-Sifiliograficas. 2015;106:477–472.
27. Prignano F, Ricceri F, Pescitelli L, et al. Tumour necrosis factor-α antagonists in patients with concurrent psoriasis and hepatitis B or hepatitis C: a retrospective analysis of 17 patients. Br J Dermatol. 2011;164:645–647.
28. Piaserico S, Dapavo P, Conti A, et al. Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature. J Eur Acad Dermatol Venereol. 2017;31:1853–1859.
29. Viganò M, Degasperi E, Aghemo A, et al. Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management. Expert Opin Biol Ther. 2012;12:193–207.
30. Nelson DR, Lim HL, Marousis CG, et al. Activation of tumor necrosis factor-alpha system in chronic hepatitis C virus infection. Dig Dis Sci. 1997;42:2487–2494.
31. Ray RB, Meyer K, Steele R, et al. Inhibition of tumor necrosis factor (TNF-alpha)-mediated apoptosis by hepatitis C virus core protein. J Biol Chem. 1998;273:2256–2259.
32. Larrea E, Garcia N, Qian C, et al. Tumor necrosis factor alpha gene expression and the response to interferon in chronic hepatitis C. Hepatology. 1996;23:210–217.
33. Brunasso AM, Puntoni M, Gulia A, et al. Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review. Rheumatol. 2011;50:1700–1711.